500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

500.5

-0.66%↓

SANES

9.558

-0.95%↓

SAF

317.6

+1.02%↑

BBVA

18.375

-0.62%↓

BNP

86.24

-0.67%↓

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.262 -0.47

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.26

Max

1.284

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	86M
Ankstesnė atidarymo kaina	1.73
Ankstesnė uždarymo kaina	1.262

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-06 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Diana Shipping Increases Offer to Acquire Genco -- Update

2026-03-06 17:44; UTC

Įsigijimai, susijungimai, perėmimai

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

2026-03-06 22:26; UTC

Svarbiausios naujienos

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

2026-03-06 22:07; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

2026-03-06 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-06 21:37; UTC

Uždarbis

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

2026-03-06 21:25; UTC

Svarbiausios naujienos

How The Iran War Impacts Ukraine. -- Barrons.com

2026-03-06 21:17; UTC

Uždarbis

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

2026-03-06 20:50; UTC

Uždarbis

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

2026-03-06 20:46; UTC

Uždarbis

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026-03-06 20:31; UTC

Svarbiausios naujienos

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

2026-03-06 20:18; UTC

Rinkos pokalbiai

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

2026-03-06 20:12; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

2026-03-06 19:10; UTC

Rinkos pokalbiai

Svarbiausios naujienos

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

2026-03-06 18:54; UTC

Rinkos pokalbiai

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

2026-03-06 18:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

2026-03-06 18:08; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 17:49; UTC

Rinkos pokalbiai

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

2026-03-06 17:46; UTC

Svarbiausios naujienos

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

2026-03-06 17:40; UTC

Rinkos pokalbiai

Uždarbis

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

2026-03-06 17:40; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 17:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

2026-03-06 17:28; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-03-06 17:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-06 17:20; UTC

Įsigijimai, susijungimai, perėmimai

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.